[go: up one dir, main page]

WO2001000175A1 - Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides - Google Patents

Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides Download PDF

Info

Publication number
WO2001000175A1
WO2001000175A1 PCT/EP2000/005494 EP0005494W WO0100175A1 WO 2001000175 A1 WO2001000175 A1 WO 2001000175A1 EP 0005494 W EP0005494 W EP 0005494W WO 0100175 A1 WO0100175 A1 WO 0100175A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparations according
active substance
active
preparations
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005494
Other languages
German (de)
English (en)
Inventor
Gunther Berndl
Jörg Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of WO2001000175A1 publication Critical patent/WO2001000175A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention relates to preparations in the form of solid solutions of active pharmaceutical ingredients in an excipient matrix, the excipient matrix containing as a polymer component a homo- or copolymer of N-vinylpyrrolidone, and 2 to 40% by weight of a surface-active substance with an HLB value of 2 to 18, which is liquid at 20 ° C, or has a dropping point in the range from 20 to 50 ° C.
  • a polymer component a homo- or copolymer of N-vinylpyrrolidone
  • EP-A 240 904 or EP-A 240 906 enables targeted control of the properties of the formulations to be produced by targeted selection or defined blends of the auxiliaries used.
  • suitable matrix polymers it is possible, for example, to prepare preparations that continuously release the active ingredient over a longer period of time. On the other hand, it may be desirable e.g. to achieve a rapid dissolution with rapid release of the active substance in pain relievers.
  • the melt extrusion process has proven to be suitable for the production of both quick-release and slow-release preparation forms.
  • the absorption of the active substance is only possible if it is present in solution, since only dissolved active substances can pass through the intestinal wall. In the case of poorly soluble active ingredients, this can lead to insufficient absorption and the associated low bioavailability.
  • solid dispersions only has a positive influence on the bioavailability of the active ingredient if the active ingredient is also rapidly absorbable.
  • the poorly soluble active ingredient recrystallizes in the aqueous environment of the intestinal lumen, since a supersaturated active ingredient solution can result from the dissolution of the pharmaceutical form. For this reason, unsatisfactory bioavailability can often only be achieved with solid dispersions.
  • the present invention was therefore based on the object of finding mechanically stable solid preparation forms for oral use which, in particular in the case of poorly soluble active ingredients, can serve for a rapid and nevertheless long-lasting solubilization after their liberation from the pharmaceutical form.
  • a solid solution is present when the active substance is essentially molecularly dispersed in the polymer matrix (J. Pharm. Sei. 60, 1281-1302, 1971).
  • Suitable active substances are, in particular, antidiabetic agents, anti-asthmatics, hormones, in particular steroid hormones, immunosuppressants, protease inhibitors, reverse transcriptase inhibitors, cytostatics or antifungals, and also CNS-active substances or dihydropyrimidine derivatives.
  • poorly soluble or difficultly bioavailable active ingredients can be formulated according to the invention.
  • Slightly soluble means that the solubility in water at 25 ° C is below 1 mg / ml.
  • active ingredients are also referred to as hardly soluble or practically insoluble.
  • Poorly soluble active ingredients are, for example, esupron, nifedipine, nimodipine, ciclosporin or taxol.
  • Suitable surface-active substances are preferably low-molecular substances which are liquid at 20 ° C. or have a dropping point in the range from above 20 ° C. to 50 ° C., preferably up to 40 ° C. Substances with an HLB value of 7 to 18, particularly preferably 10 to 15, are preferred.
  • Suitable surface-active substances are, for example, saturated and unsaturated polyglycolized glycerides, semisynthetic glycerides, fatty acid esters or ethers of fatty alcohols, provided that they have the properties indicated above.
  • sorbitan fatty acid esters or ethoxylated sorbitan fatty acid esters such as, for example, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, are particularly suitable.
  • Macrogol-6-cetylstearyl ether or are also suitable
  • Polyoxyethylene glycerol ricinoleate-35 are particularly preferred.
  • the surface-active substances are contained in the preparations in amounts of at least 2% by weight, based on the total weight of the preparation, and up to 40% by weight, preferably 5 to 25% by weight and particularly preferably 10 to 25% by weight. -%.
  • the preparations according to the invention also contain at least one thermoplastically processable polymeric matrix auxiliary.
  • thermoplastically processable polymeric matrix auxiliary water-soluble homo- and copolymers of N-vinylpyrrolidone such as polyvinylpyrrolidone with K values according to Fikentscher from 12 to 100, in particular K 17 to K 30, or copolymers with carboxylic acid vinyl esters such as vinyl acetate or vinyl propionate, particularly preferably copovidones (VP / VAc-60/40), a copolymer of 60% by weight of N-vinylpyrrolidone and 40% by weight of vinyl acetate.
  • N-vinylpyrrolidone such as polyvinylpyrrolidone with K values according to Fikentscher from 12 to 100, in particular K 17 to K 30, or copolymers with carboxylic acid vinyl esters such as vinyl acetate or vinyl propionate, particularly preferably copovidones (VP / VAc-60/40), a copoly
  • the preparations can also contain up to 10% by weight of hydroxyalkyl-alkylcelluloses which swell in water, for example hydroxypropylmethylcellulose (HPMC), preferably those with degrees of methoxy substitution in the range of 22% and degrees of hydroxypropoxy in the range of 8%, especially preferred HPMC types with viscosities of 4000 mPas, lbUUU mpas or 100000 mPas, measured at 20 ° C in 2 wt .-% aqueous solution. HPMC types with degrees of methoxy substitution in the range from 28 to 29% and hydroxypropoxy degrees of substitution in the range from 5 to 8.5% are also suitable.
  • HPMC hydroxypropylmethylcellulose
  • polymeric matrix auxiliary The amounts of polymeric matrix auxiliary depend on the amount of active ingredient and surface-active substance used.
  • the preparations may also contain conventional pharmaceutical auxiliaries such as flavors, antioxidants, silicas, mold release agents or colorants in the amounts customary for this.
  • Preparations containing 15 to 65% by weight of copovidones, 5 to 25% by weight of polyoxyethylene glycerol trihydroxystearate, 0 to 10% by weight of hydroxypropylmethyl cellulose and 5 to 65% by weight of active compound are particularly preferred according to the invention.
  • the preparations according to the invention are produced by a melt process.
  • the process is preferably carried out without the addition of solvents.
  • the melting process is carried out in a kneader or a screw extruder.
  • Suitable kneaders are, for example, 25 kneaders from Haake or Farrell.
  • the melt is preferably produced in a screw extruder, particularly preferably a twin-screw extruder with and without kneading disks or similar mixing elements. 30 Double-screw extruders rotating in the same direction are particularly preferred.
  • processing is generally carried out at temperatures of 40 ° C. to 260 ° C., preferably 35 50 to 200 ° C.
  • the feed materials can be fed to the extruder or kneader individually or as a premix.
  • the addition is preferably in the form of powdered or granulated premixes. So can
  • the liquid or oily surface-active substance is previously mixed with another feed material to form a free-flowing granulate. It is also possible to add the surface-active substance in liquid form, for example via liquid pumps, which are preferably heated in the case of semi-solid substances
  • the starting materials are accordingly processed together to form a melt, which is processed into a homogeneous mass by introducing mechanical energy, in particular in the form of shear forces.
  • the homogeneous melt is then extruded through a die or perforated plate and subjected to shaping.
  • This can be done by knocking off the extrudate emerging in the form of a strand using the usual knock-off techniques, for example using rotating knives or by knocking off compressed air, resulting in pellets or granules.
  • the shaping can be carried out as described in EP-A 240 906, in that the extrudate emerging in the form of a strand is guided between two counter-rotating calender rolls and shaped directly into tablets.
  • the melt can be drawn out via the open extruder head and, if necessary, can be ground after solidification or can be further processed by suitable granulating devices such as roller mills or compacting units.
  • Granules or pellets can then be processed into tablets in conventional tablet presses. It is also possible to subject the preparations already obtained in the form of mechanically stable tablets to a milling process and then to compress them into tablets in a conventional manner. If desired, the tablets can then be provided with a conventional coating.
  • tablets can be obtained according to the invention which have good mechanical stability even with high proportions of liquid or semi-solid surface-active substances and do not tend to stickiness or softening.
  • Filling into capsules can be dispensed with according to the invention due to the good dimensional stability of the preparations.
  • the resulting pharmaceutical forms contain the active ingredient in the form of solid solutions in which the active ingredient is present in molecularly dispersed form.
  • the pharmaceutical forms according to the invention make it possible to sufficiently solubilize even poorly soluble active ingredients or to disperse them stably in the auxiliary matrix in an aqueous medium.
  • the preparations according to the invention After dissolving in an aqueous medium, in particular at a pH of 1, the preparations according to the invention form a stable solubilizate or a stable dispersion for at least one hour, in which the active ingredient is preferably non-crystalline. Due to their better solubility compared to conventional formulations, the preparations have an improved bioavailability.
  • a powder mixture of nimodipine and copovidone was placed in a Diosna mixer and mixed with polyoxyethylene trihydroxy stearate-40.
  • the mixture obtained in this way which consisted of 12% by weight of nimodipine, 78% by weight of copovidone and 10% by weight of polyoxyethylene glycerol trihydroxystearate-40, was fed via a metering scale into a twin-screw extruder of the type ZKS-30 (Werner & Pfleiderer ) with heated shots.
  • a vacuum of 200 mbar was applied in the penultimate shot.
  • the strand emerging from the nozzle was passed between two counter-rotating calender rolls provided with lenticular depressions and calendered into lenticular tablets weighing 250 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des préparations se présentant sous la forme de solutions solides de principes actifs pharmaceutiques contenues dans une matrice de substance auxiliaire qui contient, comme composant polymère, un homopolymère ou un copolymère de la N-vinylpyrrolidone, ainsi qu'un agent tensioactif qui est liquide à 20 DEG C ou dont le point de goutte est compris entre 20 DEG C et 50 DEG C.
PCT/EP2000/005494 1999-06-25 2000-06-15 Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides Ceased WO2001000175A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999129361 DE19929361A1 (de) 1999-06-25 1999-06-25 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361.9 1999-06-25

Publications (1)

Publication Number Publication Date
WO2001000175A1 true WO2001000175A1 (fr) 2001-01-04

Family

ID=7912675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005494 Ceased WO2001000175A1 (fr) 1999-06-25 2000-06-15 Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides

Country Status (2)

Country Link
DE (1) DE19929361A1 (fr)
WO (1) WO2001000175A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2010143074A2 (fr) 2009-06-08 2010-12-16 Abbott Gmbh & Co. Kg Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille de bcl-2
WO2012121758A1 (fr) 2010-10-29 2012-09-13 Abbvie Inc. Dispersions solides extrudées en fusion contenant un agent induisant l'apoptose
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
WO2014048783A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
WO2014048782A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
US9078921B2 (en) 2006-07-19 2015-07-14 Abbvie Deutschland Gmbh & Co Kg Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
CN109789140A (zh) * 2016-09-21 2019-05-21 伊兹瓦里诺帕玛有限责任公司 用于治疗hiv感染的药物组合物
WO2021173523A1 (fr) 2020-02-24 2021-09-02 Newave Pharmaceutical Inc. Dispersions solides extrudées à chaud contenant un inhibiteur de bcl2

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304242A1 (en) * 2003-06-27 2005-01-13 Bioprogress S.P.A. Composite product obtainable by cogrinding of a active principle with a copolymer n-vinyl-2-pyrrolidone/vinyl-acetate
EP1920767A1 (fr) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Forme posologique d'Imatinib préparée à l'état fondu.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011749A1 (fr) * 1991-12-18 1993-06-24 Warner-Lambert Company Procede de preparation d'une dispersion solide
WO1996022103A1 (fr) * 1995-01-21 1996-07-25 Cheil Foods & Chemicals, Inc. Formulations solides pour l'administration de cyclosporine a par voie orale
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
WO2000057855A1 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Auxiliaires de solubilisation pulverulents pour formes d'administration pharmaceutiques solides
WO2000057854A2 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Formes d'administration pharmaceutiques mecaniquement stables, qui contiennent des substances tensioactives liquides ou semi-solides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011749A1 (fr) * 1991-12-18 1993-06-24 Warner-Lambert Company Procede de preparation d'une dispersion solide
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
WO1996022103A1 (fr) * 1995-01-21 1996-07-25 Cheil Foods & Chemicals, Inc. Formulations solides pour l'administration de cyclosporine a par voie orale
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
WO2000057855A1 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Auxiliaires de solubilisation pulverulents pour formes d'administration pharmaceutiques solides
WO2000057854A2 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Formes d'administration pharmaceutiques mecaniquement stables, qui contiennent des substances tensioactives liquides ou semi-solides

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
US8691878B2 (en) 2003-08-28 2014-04-08 Abbvie Inc. Solid pharmaceutical dosage form
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8309613B2 (en) 2003-08-28 2012-11-13 Abbvie Inc. Solid pharmaceutical dosage form
US8333990B2 (en) 2003-08-28 2012-12-18 Abbott Laboratories Solid pharmaceutical dosage form
US8399015B2 (en) 2003-08-28 2013-03-19 Abbvie Inc. Solid pharmaceutical dosage form
US9078921B2 (en) 2006-07-19 2015-07-14 Abbvie Deutschland Gmbh & Co Kg Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US9616130B2 (en) 2006-07-19 2017-04-11 Abbvie Deutschland Gmbh & Co Kg Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
WO2010143074A2 (fr) 2009-06-08 2010-12-16 Abbott Gmbh & Co. Kg Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille de bcl-2
EP3272334A1 (fr) 2009-06-08 2018-01-24 Abbott GmbH & Co. KG Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille bcl-2
US9642796B2 (en) 2009-06-08 2017-05-09 Abbvie Inc. Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
EP2982366A1 (fr) 2009-06-08 2016-02-10 Abbott GmbH & Co. KG Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille bcl-2
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
EP4218731A2 (fr) 2010-10-29 2023-08-02 AbbVie Ireland Unlimited Company Dispersions solides extrudées à l'état fondu contenant un agent induisant l'apoptose
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
EP3219308A1 (fr) 2010-10-29 2017-09-20 AbbVie Ireland Unlimited Company Dispersions solides extrudées par fusion contenant un agent induisant l'apoptose
WO2012121758A1 (fr) 2010-10-29 2012-09-13 Abbvie Inc. Dispersions solides extrudées en fusion contenant un agent induisant l'apoptose
US9238649B2 (en) 2010-11-23 2016-01-19 Abbvie Inc. Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US10730873B2 (en) 2010-11-23 2020-08-04 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9840502B2 (en) 2010-11-23 2017-12-12 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9872861B2 (en) 2010-11-23 2018-01-23 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
WO2014048783A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
WO2014048782A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN109789140A (zh) * 2016-09-21 2019-05-21 伊兹瓦里诺帕玛有限责任公司 用于治疗hiv感染的药物组合物
WO2021173523A1 (fr) 2020-02-24 2021-09-02 Newave Pharmaceutical Inc. Dispersions solides extrudées à chaud contenant un inhibiteur de bcl2

Also Published As

Publication number Publication date
DE19929361A1 (de) 2001-01-04

Similar Documents

Publication Publication Date Title
EP1162953B1 (fr) Formes d'administration pharmaceutiques mecaniquement stables, qui contiennent des substances tensioactives liquides ou semi-solides
WO2001000175A1 (fr) Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides
EP1318799B1 (fr) Formes galeniques stables contenant des ubiquinones
DE69222182T2 (de) Verfahren für die herstellung einer festen dispersion
EP1166776B1 (fr) Procédé de préparation de formes orales solides à libération retardée
DE4031881C2 (de) Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
DE69434640T2 (de) Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
EP1001757B1 (fr) Antalgique d'action rapide
EP0596203A1 (fr) Préparations sous forme de particules solides contenant des principes actifs et des polymères hydrosolubles
EP0277459A2 (fr) Médicament à libération controlée
DE69730241T2 (de) Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
DE3424553A1 (de) Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
EP1169023B1 (fr) Procèdè de la preparation des AUXILIAIRES DE SOLUBILISATION PULVERULENTS POUR FORMES D'ADMINISTRATION PHARMACEUTIQUES SOLIDES
EP0761210A2 (fr) Procédé de fabrication de préparations pharmaceutiques à libération commandée
DE69609501T2 (de) Zusammensetzung mit natriumstärkeglycolat als grundlagenmaterial und daraus hergestellte produkte
EP1280534B1 (fr) Preparations pharmaceutiques stables au stockage contenant du torasemide
EP1142571B1 (fr) Procédé pour la production de formes galéniques solides à base de créatine et formes galéniques ainsi obtenues
WO2001007015A2 (fr) Extrudats a liberation rapide, leur procede de production et preparations pouvant etre obtenues partir desdits extrudats
EP1223960A2 (fr) Preparations de principes actifs pharmaceutiques
WO1999044588A2 (fr) Procede de production de corps moules spheriques solides contenant des principes actifs pharmaceutiques dans une matrice constituee d'un liant
DE19930454A1 (de) Feste Paroxetin enthaltende Zubereitungen
DE19901040A1 (de) Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe
DE60312635T3 (de) Zusammensetzung in Form eines festen Dispersion enthaltend Itraconazol und ein hydrophilisches Polymer mit einer verbesserten Bioverfügbarkeit
DE102008057285A1 (de) 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP